See also: Two new therapies made by Sanofi and Novo Nordisk to compete in crowded diabetes market. In the respiratory segment, oral.
While there is no clear consensus on the appropriate place in therapy for GLP-1/insulin combination products, those patients who are overweight with high A1C levels and elevated fasting and post-prandial glucose would be appropriate targets. What physicians are saying: Physicians acknowledge the convenience of once-daily fixed dosing over the use of a GLP-1 agonist in the morning and basal insulin in the evening, although the inability to titrate the basal insulin could hinder use in some patients.
But the incidence of type 1 diabetes is also on the rise. MM&M >; Channel >; Pipeline >; Lexicon developing type 1 diabetes treatment with.
Notably, data for AstraZeneca's Lynparza, Johnson & Johnson's Zytiga, and Loxo Oncology's larotrectinib highlights the move toward specialized medicine.
How are pharma, clinical, and startup execs addressing some of the biggest challenges facing their businesses today?
Merck's CETP inhibitor anacetrapib and Novartis' monoclonal antibody ACZ885 hit their primary goals in late-stage cardiovascular outcomes trials, both unexpectedly positive results that are heating up this category.
However, type 1 diabetes, typically diagnosed in children and young adults, is also on the rise.
With 18 launches scheduled by 2020, Sanofi stock is bound to get a hit or two. Sanofi SA (ADR): SNY Pipeline Is Overflowing With Potential. and cats to treatments for dengue fever, diabetes, high cholesterol, rheumatoid.
Its roots actually go back to 1718. France-based Sanofi SA (ADR) ( SNY ) is one of the world’s largest pharmaceutical companies. I mentioned where it’s headquartered because the company actually pre-dates much of America.
Article printed from InvestorPlace Media, /2016/04/sanofi-stock-sny-pipeline/
His straightforward style and low-risk value approach has won seven Best Financial Advisory awards from the Newsletter and Electronic Publishers Foundation. As of this writing, he did not hold a position in any of the aforementioned securities.
Sanofi, stockpiling diabetes assets with eyes on Novo Nordisk and Eli Lilly, inked a deal worth up to $1.7 billion to bring in a late-stage.
Last week, the company revealed that it expects diabetes sales to slip about 7% in 2015 and decline well into 2018, as new products including the inhaled insulin Afrezza and Lantus heir Toujeo underperform expectations. The quickly changing diabetes landscape has particularly affected Sanofi as the insulin Lantus, long the drugmaker's cash cow, has ceded ground around the globe to newer, longer-acting alternatives.
Sanofi ($SNY), stockpiling diabetes assets with eyes on Novo Nordisk ($NVO) and Eli Lilly ($LLY), inked a deal worth up to $1.7 billion to bring in a late-stage treatment for the disease, partnering up with Lexicon Pharmaceuticals ($LXRX).
The treatment is now in two Phase III studies in Type 1 diabetes with data expected in the second half of 2016, and Sanofi is plotting to start late-stage trials in Type 2 next year.
Sanofi's research focuses on finding innovative solutions to major public health challenges. Our areas of focus include: DIABETES. VACCINES.
55 Corporate Drive Bridgewater, NJ 08807 Content :
in the United States.
The success of this approach requires increased collaboration between our researchers, physicians and clinical research centers. Our aim is to connect fundamental research (based on biological and animal models) and clinical research (focused on human beings) to facilitate the transfer of recent scientific discoveries to the clinical care of patients. This way, we will accelerate the provision of better, more effective and targeted treatments.
You are here : Subsections menu :
Sanofi’s research focuses on finding innovative solutions to major public health challenges. Our areas of focus include: DIABETES.
Quick navigation menu : Help menu : Font size : Languages menu : Welcome to Sanofi.
R&D is one key strategic pillar of our company, committed to transforming scientific and medical advances into innovative healthcare solutions for patients.
VACCINES & INFECTIOUS DISEASES RARE DISEASES IMMUNOLOGY & INFLAMMATION CARDIOVASCULAR & METABOLISM MULTIPLE SCLEROSIS CANCER NEURODEGENERATIVE DISEASES.
Last update: January 18, 2017 Modules :
Main sections menu : R&D.